Pills of Palforzia are proven containing pharmaceutical grade peanut powder, to be used in oral immunotherapy amongst sufferers with peanut allergic reactions, manufactured by means of Aimmune Therapeutics, primarily based in Brisbane, California, on this handout acquired by means of Reuters on February 5, 2020. Aimmune Therapeutics/Handout by way of REUTERS/Document Photograph Achieve Licensing Rights
ZURICH, Sept 4 (Reuters) – Nestle (NESN.S) has divested its peanut hypersensitivity remedy industry Palforzia, the Swiss meals corporate stated on Monday, following its strategic overview of the department.
Nestle stated it has offloaded Palforzia to Stallergenes Greer, a biopharmaceutical corporate which makes a speciality of the prognosis and remedy of allergic reactions.
Nestle will obtain milestone bills and ongoing royalties from Stallergenes Greer, it stated.
Reporting by means of John Revill, Enhancing by means of Friederike Heine
Our Requirements: The Thomson Reuters Agree with Ideas.
